“Of course, we are waiting for larger cohorts. In addition, considering the importance of IL-6 in the COVID-19 cytokine storm, I am looking forward to seeing the impact of the use of IL-6 inhibitors in the progression of COVID-19 in IMIDs,” Dr. Velloso says.
Katie Robinson is a medical writer based in New York.
References
- Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639.
- Hyrich KL, Machado PM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol. 2021 Feb;17(2):71–72.
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology. 2020 Aug;159(2):481–491.e3.
- Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859–866.
- Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. J Allergy Clin Immunol. 2021 Jan;147(1):60–71.
- Velloso LA. Use of tumor necrosis factor inhibitors during the COVID-19 pandemic—evidence in favor of monotherapy. JAMA Netw Open. 2021 Oct 1;4(10):e2129707.
